| MeSH term | MeSH ID | Detail |
|---|---|---|
| Otitis Media | D010033 | 12 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Whooping Cough | D014917 | 6 associated lipids |
| Fecal Impaction | D005244 | 1 associated lipids |
Total
4
ERYTHROMYCIN ESTOLATE
ERYTHROMYCIN ESTOLATE is a lipid of Polyketides (PK) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 675 references associated with ERYTHROMYCIN ESTOLATE in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for ERYTHROMYCIN ESTOLATE
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with ERYTHROMYCIN ESTOLATE
All references with ERYTHROMYCIN ESTOLATE
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Villa P et al. | Erythromycin toxicity in primary cultures of rat hepatocytes. | 1985 Aug-Sep | Xenobiotica | pmid:4072263 |
| Villa P et al. | Protective effect of diosmetin on in vitro cell membrane damage and oxidative stress in cultured rat hepatocytes. | 1992 | Toxicology | pmid:1609428 |
| Davila JC et al. | Protective effect of flavonoids on drug-induced hepatotoxicity in vitro. | 1989 | Toxicology | pmid:2756528 |
| Morgan RE et al. | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. | 2013 | Toxicol. Sci. | pmid:23956101 |
| Morgan RE et al. | Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. | 2010 | Toxicol. Sci. | pmid:20829430 |
| de Longueville F et al. | Use of a low-density microarray for studying gene expression patterns induced by hepatotoxicants on primary cultures of rat hepatocytes. | 2003 | Toxicol. Sci. | pmid:12883083 |
| Zidek N et al. | Acute hepatotoxicity: a predictive model based on focused illumina microarrays. | 2007 | Toxicol. Sci. | pmid:17522070 |
| Sorensen EM and Acosta D | Erythromycin estolate-induced toxicity in cultured rat hepatocytes. | 1985 | Toxicol. Lett. | pmid:4060187 |
| Gaeta GB et al. | Characterization of the effects of erythromycin estolate and erythromycin base on the excretory function of the isolated rat liver. | 1985 | Toxicol. Appl. Pharmacol. | pmid:2992120 |
| Pari L and Uma A | Protective effect of Sesbania grandiflora against erythromycin estolate-induced hepatotoxicity. | 2003 Sep-Oct | Therapie | pmid:14682193 |
| Hillyer D | Is erythromycin indicated in pregnancy? | 1992 | RN | pmid:1594870 |
| Lai CC et al. | Analysis of a commercial preparation of erythromycin estolates by tandem mass spectrometry and high performance liquid chromatography/electrospray ionization tandem mass spectrometry using an ion trap mass spectrometer. | 2000 | Rapid Commun. Mass Spectrom. | pmid:10717658 |
| Henry J et al. | Plasma and salivary concentrations of erythromycin after administration of three different formulations. | 1980 | Postgrad Med J | pmid:7220406 |
| Garnham JC | Trade names or approved names. Part III. Special cases. Clinical trials. | 1974 | Postgrad Med J | pmid:4465771 |
| Ramin U and Wollmann H | [Problems in the determination of water content of lubomycin B capsules]. | 1990 | Pharmazie | pmid:2080216 |
| Potthast H et al. | [Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state]. | 1995 | Pharmazie | pmid:7886126 |
| Drew R and Piestly BG | Effect of chlorpromazine and erythromycin on bile salt-induced cholestasis in the rat. | 1979 | Pharmacology | pmid:572556 |
| Dujovne CA and Salhab AS | Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems. | 1980 | Pharmacology | pmid:7403251 |
| Pari L and Murugan P | Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. | 2004 | Pharmacol. Res. | pmid:14998559 |
| Krowchuk D and Seashore JH | Complete biliary obstruction due to erythromycin estolate administration in an infant. | 1979 | Pediatrics | pmid:514726 |
| Langley JM et al. | Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. | 2004 | Pediatrics | pmid:15231980 |
| Snellman LW et al. | Duration of positive throat cultures for group A streptococci after initiation of antibiotic therapy. | 1993 | Pediatrics | pmid:8502522 |
| Halperin SA et al. | Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. | 1997 | Pediatrics | pmid:9200361 |
| Halperin SA et al. | A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive bordetella pertussis infection. | 1999 | Pediatrics | pmid:10506267 |
| Hoppe JE | Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group. | 1992 | Pediatr. Infect. Dis. J. | pmid:1565532 |
| Torre D et al. | Erythromycin estolate for treatment of pertussis. | 1986 Nov-Dec | Pediatr Infect Dis | pmid:3797311 |
| Derrick CW et al. | Erythromycin in the treatment of streptococcal infections. | 1986 Jan-Feb | Pediatr Infect Dis | pmid:3945572 |
| Ginsburg CM | Pharmacology of erythromycin in infants and children. | 1986 Jan-Feb | Pediatr Infect Dis | pmid:3753798 |
| Ginsburg CM et al. | Management of group A streptococcal pharyngitis: a randomized controlled study of twice-daily erythromycin ethylsuccinate versus erythromycin estolate. | 1982 Nov-Dec | Pediatr Infect Dis | pmid:6761656 |
| Ginsburg CM | A prospective study on the incidence of liver function abnormalities in children receiving erythromycin estolate, erythromycin ethylsuccinate or penicillin V for treatment of pneumonia. | 1986 Jan-Feb | Pediatr Infect Dis | pmid:3080735 |
| Griffith RS | Pharmacology of erythromycin in adults. | 1986 Jan-Feb | Pediatr Infect Dis | pmid:3511455 |
| Klein MD | Streptococcal pharyngitis in children. | 1989 | Pediatr Emerg Care | pmid:2690022 |
| Koranyi KI et al. | Evaluation of bacitracin ointment in the treatment of impetigo. | 1976 | Ohio State Med J | pmid:958658 |
| Kunii O | [Toxic hepatitis induced by antibiotics]. | 1985 | Nippon Rinsho | pmid:3900467 |
| REED C and RITCHIE F | Toxic jaundice due to propionyl erythromycin ester lauryl sulphate ("Ilosone"). | 1962 | Med. J. Aust. | pmid:14037477 |
| Abernathy CO et al. | Cytotoxic effects of erythromycin estolate and chlorpromazine on hepatocytes isolated from rats of varying ages: a brief note. | 1980 | Mech. Ageing Dev. | pmid:7354660 |
| Gaeta GB et al. | Prevention of the toxicity of erythromycin estolate in the perfused rat liver by endotoxin. | 1986 | Life Sci. | pmid:3526067 |
| Farre M | Erythromycin propionate and estolate. | 1988 | Lancet | pmid:2898648 |
| SOUTH MA et al. | FAILURE OF ERYTHROMYCIN ESTOLATE THERAPY IN IN UTERO SYPHILIS. | 1964 | JAMA | pmid:14197148 |
| HAVENS WP | Cholestatic jaundice in patients treated with erythromycin estolate. | 1962 | JAMA | pmid:13905478 |
| Brown ST et al. | Comparison of erythromycin base and estolate in gonococcal urethritis. | 1977 | JAMA | pmid:408522 |
| Punch PI et al. | The release of insoluble antibiotics from collagen ocular inserts in vitro and their insertion into the conjunctival sac of cattle. | 1987 | J. Vet. Pharmacol. Ther. | pmid:3586121 |
| Albarellos GA et al. | Pharmacokinetics of erythromycin after the administration of intravenous and various oral dosage forms to dogs. | 2008 | J. Vet. Pharmacol. Ther. | pmid:19000270 |
| SanFilippo A | Infantile hypertrophic pyloric stenosis related to ingestion of erythromycine estolate: A report of five cases. | 1976 | J. Pediatr. Surg. | pmid:1263054 |
| Ginsburg CM et al. | Concentrations of erythromycin in serum and tonsil: comparison of the estolate and ethyl succinate suspensions. | 1976 | J. Pediatr. | pmid:792404 |
| Trujillo H | Cefadroxil monohydrate versus erythromycin in paediatric patients. | 1981 | J. Int. Med. Res. | pmid:7227625 |
| Thibault N et al. | Effect of tauroursodeoxycholate on actin filament alteration induced by cholestatic agents. A study in isolated rat hepatocyte couplets. | 1993 | J. Hepatol. | pmid:8151096 |
| Chen KC et al. | Amine content of vaginal fluid from untreated and treated patients with nonspecific vaginitis. | 1979 | J. Clin. Invest. | pmid:447831 |
| Villa P et al. | Effects of a new fluorinated macrolide (P-0501A) and other erythromycins on drug metabolizing enzymes in rat liver. | 1986 | J. Antibiot. | pmid:3084433 |
| Selenke WM et al. | Nonantibiotic effects of macrolide antibiotics of the oleandomycin-erythromycin group with special reference to their "steroid-sparing" effects. | 1980 | J. Allergy Clin. Immunol. | pmid:6966289 |